Purpose Of Review: Glioblastoma (GBM), the most prevalent primary brain malignancy in adults, poses significant challenges in terms of treatment. Current therapeutic strategies for GBM patients involve maximal safe resection, followed by radiotherapy with concurrent and adjuvant temozolomide. However, despite this multimodal approach for GBM, the prognosis of GBM patients remains dismal because of their inherent primary and secondary resistances to treatments.
Recent Findings: Several molecular and cellular mechanisms, including the presence of the blood-brain barrier (BBB), contribute to these resistances. The BBB, comprising multiple layers surrounding brain vessels, acts as a barrier limiting effective drug delivery to the brain. Invasive and noninvasive tools to deliver drugs and pharmaceutical formulations locally or systemically are continuously evolving to overcome the BBB in GBM toward improving drug bioavailability in the brain and reducing systemic toxicities.
Summary: Preliminary studies utilizing these approaches have demonstrated promising results in terms of safety and signals of efficacy during early-phase clinical trials. However, further work through additional clinical trials is necessary to evaluate the potential clinical benefits for GBM patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566587 | PMC |
| http://dx.doi.org/10.1097/CCO.0000000000000990 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of glioma metabolism-related gene ALPK1 on tumor immune heterogeneity and the regulation of the TGF-β pathway.
Front Immunol
January 2025
Department of Neurological Care Unit, The First Affiliated Hospital of YangTze University, Jingzhou, Hubei, China.
Background: Recent years have seen persistently poor prognoses for glioma patients. Therefore, exploring the molecular subtyping of gliomas, identifying novel prognostic biomarkers, and understanding the characteristics of their immune microenvironments are crucial for improving treatment strategies and patient outcomes.
Methods: We integrated glioma datasets from multiple sources, employing Non-negative Matrix Factorization (NMF) to cluster samples and filter for differentially expressed metabolic genes.
FTO Suppresses Proliferation and Induces Apoptosis of T98G Glioblastoma Cells via N6-methyladenosine Modification of GSTO1.
Neurochem Res
January 2025
Dept Intens Care Unit, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, No.453, Stadium Road, Hangzhou, Zhejiang, 310007, China.
Glioblastoma (GBM) is the most malignant type of glioma with a very poor prognosis. N6-methyladenosine (m6A) is well-documented to be involved in GBM progression, and FTO is a demethylase. GSTO1 is also associated with tumor progression.
View Article and Find Full Text PDFPreoperative anemia is associated with prolonged hospital stay and increased facility discharges after glioblastoma resection.
Front Surg
January 2025
Saint Luke's Cancer Institute, Saint Luke's Hospital, Kansas, MO, United States.
Background: Despite numerous operative and non-operative treatment modalities, patients with glioblastoma (GBM) have a dismal prognosis. Identifying predictors of survival and recurrence is an essential strategy for guiding treatment decisions, and existing literature demonstrates associations between hematologic data and clinical outcomes in cancer patients. As such, we provide a novel analysis that examines associations between preoperative hematologic data and postoperative outcomes following GBM resection.
View Article and Find Full Text PDFBrain tumor enhancement prediction from pre-contrast conventional weighted images using synthetic multiparametric mapping and generative artificial intelligence.
Quant Imaging Med Surg
January 2025
Radiology and Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands.
Background: Gadolinium-based contrast agents (GBCAs) are usually employed for glioma diagnosis. However, GBCAs raise safety concerns, lead to patient discomfort and increase costs. Parametric maps offer a potential solution by enabling quantification of subtle tissue changes without GBCAs, but they are not commonly used in clinical practice due to the need for specifically targeted sequences.
View Article and Find Full Text PDFEnhancement of the nontumor component in newly diagnosed glioblastoma as a more accurate predictor of local recurrence location: a multicenter study.
Quant Imaging Med Surg
January 2025
Department of Radiology, Medical Imaging Institute of Tianjin, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Although the spatial heterogeneity of glioblastoma (GBM) can be clearly mapped by the habitats generated by magnetic resonance imaging (MRI), the means to accurately predicting the spatial location of local recurrence (SLLR) remains a significant challenge. The aim of this study was to identify the different degrees enhancement of GBM, including the nontumor component and tumor component, and determine their relationship with SLLR.
Methods: A retrospective analysis was performed from three tertiary medical centers, totaling 728 patients with 109 radiation-induced temporal lobe necrosis (TLN) of nasopharyngeal carcinoma (NPC) and 619 with GBM.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!